Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 1998-11-02 (27 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: ROQUEMAURE (30150), Gard
PHARMACIE DU MAGNOLIA : revenue, balance sheet and financial ratios
PHARMACIE DU MAGNOLIA is a French company
founded 27 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in ROQUEMAURE (30150),
this company of category PME
shows in 2024 a revenue of 2.1 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DU MAGNOLIA (SIREN 421366469)
Indicator
2024
2023
2022
Revenue
2 088 683 €
N/C
2 177 487 €
Net income
-30 466 €
37 185 €
52 752 €
EBITDA
-9 431 €
N/C
92 384 €
Net margin
-1.5%
N/C
2.4%
Revenue and income statement
In 2024, PHARMACIE DU MAGNOLIA achieves revenue of 2.1 M€. Activity remains stable over the period (CAGR: -2.1%). After deducting consumption (1.5 M€), gross margin stands at 622 k€, i.e. a rate of 30%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -9 k€, representing -0.5% of revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -30 k€ (-1.5% of revenue), which will impact equity.
Revenue (2024)
?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production
2 088 683 €
Gross margin (2024)
?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed
621 693 €
EBITDA (2024)
?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity
-9 431 €
EBIT (2024)
?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals
-27 489 €
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
-30 466 €
EBITDA margin (2024)
?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability 5-10% : Average < 5% : Low
-0.5%
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 3%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 82%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
3.284%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
81.843%
Cash flow / Revenue (2024)
?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates
-0.439%
Repayment capacity (2024)
?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent 3-5 years : Fair > 5 years : Warning
-3.976
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE DU MAGNOLIA
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2022
2023
2024
Debt ratio
17.681
9.585
3.284
Financial autonomy
73.971
79.897
81.843
Repayment capacity
2.887
None
-3.976
Cash flow / Revenue
3.229%
None%
-0.439%
Sector positioning
Debt ratio
3.282024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Excellent
In 2024, the debt ratio of PHARMACIE DU MAGNOLIA (3.28) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
81.84%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Excellent+8 pts over 3 years
In 2024, the financial autonomy of PHARMACIE DU MAGNOLIA (81.8%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
-3.98 years2024
2022
2024
Q1: 0.52 years
Med: 3.19 years
Q3: 7.6 years
Excellent-18 pts over 2 years
In 2024, the repayment capacity of PHARMACIE DU MAGNOLIA (-3.98) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 157.34. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
157.345
Interest coverage (2024)
?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable 1.5-3 : Acceptable < 1.5 : Risk
-4.506
Liquidity indicators evolution PHARMACIE DU MAGNOLIA
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2022
2023
2024
Liquidity ratio
243.106
213.733
157.345
Interest coverage
0.99
None
-4.506
Sector positioning
Liquidity ratio
157.342024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Average-26 pts over 3 years
In 2024, the liquidity ratio of PHARMACIE DU MAGNOLIA (157.34) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
-4.51x2024
2022
2024
Q1: 0.0x
Med: 2.35x
Q3: 7.73x
Average
In 2024, the interest coverage of PHARMACIE DU MAGNOLIA (-4.5x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 7 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 36 days. Favorable situation: supplier credit is longer than customer credit by 29 days. Inventory turnover is 40 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 44 days of revenue, i.e. 253 k€ to permanently finance.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
252 772 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
7 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
36 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
40 j
WCR in days of revenue (2024)
?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management
44 j
WCR and payment terms evolution PHARMACIE DU MAGNOLIA
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2022
2023
2024
Operating WCR
271 729 €
0 €
252 772 €
Inventory turnover (days)
39
0
40
Customer payment term (days)
7
0
7
Supplier payment term (days)
36
0
36
Positioning of PHARMACIE DU MAGNOLIA in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE DU MAGNOLIA is estimated at
1 336 096 €
(range 1 119 960€ - 1 683 537€).
The price/revenue ratio is 0.64x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1119k€1336k€1683k€
1 336 096 €Range: 1 119 960€ - 1 683 537€
NAF 5 année 2024
Valuation method used
Revenue Multiple
2 088 683 €
×
0.64x
=1 336 097 €
Range: 1 119 960€ - 1 683 538€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DU MAGNOLIA with other companies in the same sector:
Frequently asked questions about PHARMACIE DU MAGNOLIA
What is the revenue of PHARMACIE DU MAGNOLIA ?
The revenue of PHARMACIE DU MAGNOLIA in 2024 is 2.1 M€.
Is PHARMACIE DU MAGNOLIA profitable?
PHARMACIE DU MAGNOLIA recorded a net loss in 2024.
Where is the headquarters of PHARMACIE DU MAGNOLIA ?
The headquarters of PHARMACIE DU MAGNOLIA is located in ROQUEMAURE (30150), in the department Gard.
Where to find the tax return of PHARMACIE DU MAGNOLIA ?
The tax return of PHARMACIE DU MAGNOLIA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DU MAGNOLIA operate?
PHARMACIE DU MAGNOLIA operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart